NASDAQ : NRIX
Nurix Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 27.12 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.96B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.93B |
| Enterprise Value | 1.94B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 109.25M |
| Shares Outstanding | 109.25M |
| Shares Change (YoY) | +32.80% |
| Shares Change (QoQ) | +4.56% |
| Owned by Insiders (%) | 0.89% |
| Owned by Institutions (%) | 83.69% |
| Float | 79.58M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 9.97 |
| Forward PE | n/a |
| PS Ratio | 4.17 |
| Forward PS | 8.80 |
| PB Ratio | 3.02 |
| P/TBV Ratio | 3.02 |
| P/FCF Ratio | 7.92 |
| P/OCF Ratio | 7.72 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 6.60 |
| EV / Sales | 2.77 |
| EV / EBITDA | 6.53 |
| EV / EBIT | 6.71 |
| EV / FCF | 5.26 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.44 |
| Quick Ratio | 8.19 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.21 |
| Debt / FCF | 0.18 |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 43.99% |
| Return on Assets (ROA) | 21.08% |
| Return on Invested Capital (ROIC) | 24.76% |
| Return on Capital Employed (ROCE) | 27.21% |
| Weighted Average Cost of Capital (WACC) | 13.95% |
| Revenue Per Employee | $2.21M |
| Profits Per Employee | $930,211 |
| Employee Count | 317 |
| Asset Turnover | 0.82 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 13.34M |
| Effective Tax Rate | 4.33% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.82 |
| 52-Week Price Change | +129.06% |
| 50-Day Moving Average | 24.98 |
| 200-Day Moving Average | 20.18 |
| Relative Strength Index (RSI) | 63.81 |
| Average Volume (20 Days) | 2,622,544 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 20.61M |
| Short Previous Month | 17.66M |
| Short % of Shares Out | 18.86% |
| Short % of Float | 25.90% |
| Short Ratio (days to cover) | 10.30 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 701.94M |
| Gross Profit | 367.86M |
| Operating Income | 289.66M |
| Pretax Income | 308.21M |
| Net Income | 294.88M |
| EBITDA | 297.77M |
| EBIT | 289.66M |
| Earnings Per Share (EPS) | $2.69 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.05B |
| Total Debt | 65.33M |
| Net Cash | 982.92M |
| Net Cash Per Share | $9.00 |
| Equity (Book Value) | 968.31M |
| Book Value Per Share | 8.87 |
| Working Capital | 972.95M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 379.31M |
| Capital Expenditures | -9.50M |
| Depreciation & Amortization | 8.11M |
| Net Borrowing | n/a |
| Free Cash Flow | 369.81M |
| FCF Per Share | $3.38 |
Margins
| Measure | Value |
|---|
| Gross Margin | 52.41% |
| Operating Margin | 41.27% |
| Pretax Margin | 43.91% |
| Profit Margin | 42.01% |
| EBITDA Margin | 42.42% |
| EBIT Margin | 41.27% |
| FCF Margin | 52.68% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -32.80% |
| Shareholder Yield | -32.80% |
| Earnings Yield | 10.03% |
| FCF Yield | 12.63% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $34.50 |
| Price Target Difference | 28.73% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 55.86% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 6.13 |
| Piotroski F-Score | 7 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |